Table 3.
Group | Total | Duke's A | Dukes' B | Dukes' C | Dukes' D | Dukes' A+B | Dukes' C+D |
Screening phase | |||||||
1 | 13 | 8 (61.5) | 4 (30.7) | 1 (7.6) | 0 | 12 (92.3)* | 1 (7.6) |
2 | 6 | 0 | 0 | 5 (83.3) | 1 (16.7) | 0 | 6 (100.0) |
3 | 7 | 1 (14.3) | 1 (14.3) | 3 (42.8) | 2 (28.6) | 2 (28.6) | 5 (71.4) |
Follow up phase | |||||||
1 | 21 | 2 (9.5) | 12 (57.0) | 5 (23.7) | 2 (9.5) | 14 (66.5)† | 7 (33.2) |
2 | 23 | 1 (4.3) | 12 (51.6) | 6 (25.8) | 4 (17.2) | 13 (55.9) | 10 (43.0) |
3 | 13 | 1 (7.7) | 5 (38.5) | 5 (38.5) | 2 (15.4) | 6 (46.2) | 7 (53.9) |
*The difference between the Dukes' stage of tumours was significant (p<0.001). There were significantly more cases with tumours of Dukes' stage A+B in group 1 than group 2 (p<0.001) and group 3 (p=0.016).
†There was no difference in Dukes's stage between groups during follow up.